Русский
The rationale for re-administration of genetically engineered biological drugs in patients with COVID-19
DOI: https://dx.doi.org/10.18565/pharmateca.2021.8.11-14
I.S. Burashnikova
Kazan State Medical Academy – Branch Campus of the Russian Medical Academy of Continuous Professional Education, Kazan, Russia, https://orcid.org/0000-0002-8511-5696
Currently, there are no evidence-based data to recommend the use of repeated doses of interleukin-6 (IL-6) blockers for the treatment of patients with COVID-19. To date, the data on the effectiveness of IL-6 blockers are contradictory. The use of drugs of this group can increase the risk of suppression of the immune system with a decrease in resistance to infectious agents.
Keywords: interleukin-6 blockers, genetically engineered biological drugs, COVID-19, coronavirus infection
Similar Articles
